13.1.2. Headers  All output should have the following header at the top left of each page: Stemline Therapeutics, Inc. Protocol No. STML –701-0114  All output should have Page n of N at the top or bottom right corner of each page. TLFs should be internally paginated in relation to the total length (ie, the page number should appear sequentially as page n of N, where N is the total number of pages in the table).  The date (date output was generated) should appear along with program name and location as the last footer on each page. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 46 of 63 13.1.3. Display Titles  Each TLF should be identified by the designation and a numeral. (ie, Table 14.1.1). ICH E3 numbering is strongly recommended but sponsor preferences should be obtained prior to final determination. A decimal system (x.y and x.y.z) should be used to identify TLFs with related contents. The title is centered. The analysis set should be identified on the line immediately following the title. The title and table designation are single spaced. A solid line spanning the margins will separate the display titles from the column headers. There will be 1 blank line between the last title and the solid line. Table x.y.z First Line of Title Second Line of Title if Needed Population Description 13.1.4. Column Headers  Column headings should be displayed immediately below the solid line described above in initial upper-case characters.  In the case of efficacy tables, the variable (or characteristic) column will be on the far left followed by the treatment group columns and total column (if applicable). P-values may be presented under the total column or in separate p-value column (if applicable). Within- treatment comparisons may have p-values presented in a row beneath the summary statistics for that treatment.  For numer ic variables, include “unit” in column or row heading when appropriate.  Analysis set sizes will be presented for each treatment group in the column heading as (N=xx) (or in the row headings if applicable). This is distinct from the ‘n’ used for the descrip tive statistics representing the number of patients in the analysis set.  The order of treatments in the tables and listings will be Placebo first in the case of placeb o controlled studies and Active comparators first in the case of active comparator trials, fo llowed by a total column (if applicable). 13.1.5.